- Histologically or cytologically confirmed adenocarcinoma of the prostate
- Patients must have progressive hormone-refractory prostate cancer (HRPC): patients
must have undergone primary hormone treatment (e.g. orchiectomy or gonadotropin
releasing hormone analog with or without antiandrogens). For patients who received
antiandrogen therapy, disease progression must have been determined after antiandrogen
discontinuation
- Progressive disease based on either non-measurable disease and an elevated PSA OR
measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Prior thalidomide, anti-vascular endothelial growth factor (VEGF) therapy, VEGF
receptor inhibitor, platelet-derived growth factor (PDGF) receptor inhibitor or
anti-angiogenic treatment of any kind including investigational therapy
- Prior chemotherapy
- Uncontrolled pain at baseline, impending complication from bone metastasis (fracture
and/or compression) and/or presence of urinary obstruction (urinary retention,
hydronephrosis)
- History of cardiac dysfunction, QT interval corrected for heart rate (QTc) >450 msec
- Central Nervous System (CNS) involvement